• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    1/18/23 12:31:09 PM ET
    $CCM
    $CKPT
    $CLXT
    $DMTK
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CCM alert in real time by email

    Gainers

    • Ontrak (NASDAQ:OTRK) shares increased by 145.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 128.7 million shares, making up 47983.4% of its average full-day volume over the last 100 days. The company's market cap stands at $38.1 million.
    • Ontrak (NASDAQ:OTRKP) shares moved upwards by 50.4% to $1.35. Trading volume for Ontrak's stock is 310.5K as of 12:30 EST. This is 1716.4% of its average full-day volume over the last 100 days.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 37.11% to $6.76. As of 12:30 EST, TC BioPharm (Holdings)'s stock is trading at a volume of 21.3 million, which is 8237.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $268.6 million.
    • Sigilon Therapeutics (NASDAQ:SGTX) stock rose 36.98% to $0.57. The current volume of 6.9 million shares is 11827.2% of Sigilon Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $18.3 million.
    • Concord Medical Services (NYSE:CCM) shares increased by 22.28% to $1.55. The company's market cap stands at $67.4 million.
    • Tricida (NASDAQ:TCDA) stock moved upwards by 18.56% to $0.16. Trading volume for Tricida's stock is 44.2 million as of 12:30 EST. This is 331.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.1 million.

    Losers

    • Universe Pharmaceuticals (NASDAQ:UPC) stock fell 22.9% to $0.9 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 3.8 million shares, making up 1723.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.4 million.
    • Checkpoint Therapeutics (NASDAQ:CKPT) shares fell 20.99% to $5.51. As of 12:30 EST, Checkpoint Therapeutics's stock is trading at a volume of 355.7K, which is 315.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $56.5 million.
    • Calyxt (NASDAQ:CLXT) stock decreased by 19.31% to $0.29. Calyxt's stock is trading at a volume of 4.4 million shares as of 12:30 EST. This is 254.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million.
    • DermTech (NASDAQ:DMTK) stock declined by 18.73% to $4.34. DermTech's stock is trading at a volume of 1.0 million shares as of 12:30 EST. This is 149.1% of its average full-day volume over the last 100 days. The company's market cap stands at $131.1 million.
    • PAVmed (NASDAQ:PAVM) shares fell 18.58% to $0.52. Trading volume for this security as of 12:30 EST is 1.2 million, which is 175.9% of its average full-day volume over the last 100 days. The company's market cap stands at $48.2 million.
    • Vapotherm (NYSE:VAPO) stock declined by 16.49% to $1.52. As of 12:30 EST, Vapotherm's stock is trading at a volume of 186.3K, which is 27.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $40.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCM
    $CKPT
    $CLXT
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Checkpoint Therapeutics Inc.
    $CKPT
    1/13/2025$9.00Buy
    D. Boral Capital
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    DermTech Inc.
    $DMTK
    7/18/2022$48.00Outperform
    Oppenheimer
    Checkpoint Therapeutics Inc.
    $CKPT
    7/14/2022$7.00Buy
    B. Riley Securities
    DermTech Inc.
    $DMTK
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    Vapotherm Inc.
    $VAPO
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    Tricida Inc.
    $TCDA
    4/13/2022$25.00Buy
    Goldman
    Vapotherm Inc.
    $VAPO
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    12/14/23 5:10:06 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

    4/A - VAPOTHERM INC (0001253176) (Issuer)

    10/4/23 4:11:34 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.

    3/12/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    SEC Filings

    View All

    SEC Form DEF 14A filed by PAVmed Inc.

    DEF 14A - PAVmed Inc. (0001624326) (Filer)

    2/24/26 4:15:16 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by PAVmed Inc.

    D - PAVmed Inc. (0001624326) (Filer)

    2/17/26 8:39:16 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by PAVmed Inc.

    PRE 14A - PAVmed Inc. (0001624326) (Filer)

    2/13/26 5:00:23 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:33 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:12 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.

    3/12/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Checkpoint Therapeutics Inc.

    SC 13G/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    11/14/24 4:49:25 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $CCM
    $CKPT
    $CLXT
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Checkpoint Therapeutics with a new price target

    D. Boral Capital initiated coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $9.00

    1/13/25 8:29:55 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Ontrak with a new price target

    ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

    12/5/23 8:03:01 AM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Oppenheimer resumed coverage on DermTech with a new price target

    Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

    7/18/22 9:13:48 AM ET
    $DMTK
    Medical Specialities
    Health Care